A PROTAC based on TNA (threose nucleic acid) and DNA has been developed to effectively target and degrade MYC in triple-negative breast cancer cells, which provides a promising therapeutic intervention for triple-negative breast cancer.179. Here, MYC is linked to triple-negative breast carcinoma.